SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-176021
Filing Date
2022-06-17
Accepted
2022-06-17 08:12:55
Documents
15
Period of Report
2022-06-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d272393d8k.htm   iXBRL 8-K 35657
2 EX-10.1 d272393dex101.htm EX-10.1 64223
3 EX-99.1 d272393dex991.htm EX-99.1 11646
7 GRAPHIC g272393dsp005.jpg GRAPHIC 3270
  Complete submission text file 0001193125-22-176021.txt   271007

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA atai-20220615.xsd EX-101.SCH 2836
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20220615_lab.xml EX-101.LAB 18670
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20220615_pre.xml EX-101.PRE 11670
9 EXTRACTED XBRL INSTANCE DOCUMENT d272393d8k_htm.xml XML 3580
Mailing Address 180 VARICK STREET NEW YORK NY 10014
Business Address 180 VARICK STREET NEW YORK NY 10014 (617) 699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 221022437
SIC: 2834 Pharmaceutical Preparations